Oppenheimer Maintains Hold Rating on Cellectar Biosciences with $18.00 Average Price Target

Oppenheimer maintains a Hold rating for Cellectar Biosciences (CLRB) with a consensus Moderate Buy rating and average price target of $18.00. CLRB's market cap is $11.83M and has a P/E ratio of -0.22.

Cellectar Biosciences (CLRB), a biotechnology company, experienced a volatile trading day on Thursday, August 14, 2025, with its stock price fluctuating between $4.33 and $4.94. Despite no significant changes in the stock's price, the company's stock has fallen in six of the last ten trading days, resulting in an 8.68% decline over this period [1].

The stock's movement indicates a potential buying opportunity, as it lies in the lower part of a strong rising trend in the short term. Analysts predict the stock could rise by 89.62% in the next three months, with a 90% probability of holding a price between $7.71 and $25.35 [1]. However, several negative signals have been issued, including sell signals from both short and long-term moving averages and a sell signal from the 3-month Moving Average Convergence Divergence (MACD) [1].

On the earnings front, Cellectar Biosciences is scheduled to announce Q2 2025 earnings results on Thursday, August 14, 2025, before the market opens. The consensus EPS estimate is -$3.70, with the company having beaten EPS estimates 0% of the time over the last year and revenue estimates 0% of the time over the same period [2]. The company's Q2 GAAP EPS of -$3.39 was a beat by $0.31, with the company reporting approximately $11.0 million in cash and cash equivalents as of June 30, 2025 [3].

Oppenheimer maintains a Hold rating for Cellectar Biosciences (CLRB) with a consensus Moderate Buy rating and an average price target of $18.00. The company's market cap is $11.83 million, and its P/E ratio is -0.22 [1].

References:

[1] https://stockinvest.us/stock/CLRB
[2] https://seekingalpha.com/news/4484856-cellectar-biosciences-q2-2025-earnings-preview
[3] https://seekingalpha.com/news/4485266-cellectar-biosciences-gaap-eps-of-3_39-beats-by-0_31